After engagement of the B cell receptor for antigen, the Syk protein-tyrosine kinase becomes phosphorylated on multiple tyrosines, some of which serve as docking sites for downstream effectors with SH2 or other phosphotyrosine binding domains. The most frequently identified binding partner for catalytically active Syk identified in a yeast two-hybrid screen was the p85 regulatory subunit of phosphoinositide 3-kinase. The C-terminal SH2 domain of p85 was sufficient for mediating an interaction with tyrosine-phosphorylated Syk. Interestingly, this domain interacted with Syk at phosphotyrosine 317, a site phosphorylated in trans by the Src family kinase, Lyn, and identified previously as a binding site for c-Cbl. This site interacted preferentially with the p85 C-terminal SH2 domain compared with the c-Cbl tyrosine kinase binding domain. Molecular modeling studies showed a good fit between the p85 SH2 domain and a peptide containing phosphotyrosine 317. Tyr-317 was found to be essential for Syk to support phagocytosis mediated by Fc␥RIIA receptors expressed in a heterologous system. These studies establish a new type of p85 binding site that can exist on proteins that serve as substrates for Src family kinases and provide a molecular explanation for observations on direct interactions between Syk and phosphoinositide 3-kinase.Syk is a 72-kDa protein-tyrosine kinase that plays a central role in coupling immune recognition receptors to multiple downstream signaling pathways (1,2). This function is a property of both its catalytic activity and its ability to participate in interactions with effector proteins containing SH2 1 domains.For example, after the engagement of antigen receptors on B cells, Syk is phosphorylated on three tyrosines that lie within the linker B region, which separates the N-terminal tandem pair of SH2 domains from the catalytic domain (3). Phosphorylation of the first, at Tyr-317 (numbering based on the murine Syk sequence), is catalyzed primarily by Lyn, a Src family kinase. This creates a docking site for c-Cbl, a potential negative regulator of Syk-dependent signaling (4, 5). Indeed, mutant forms of Syk containing substitutions of Phe for Tyr at position 317 exhibit enhanced activity in B cells and mast cells (3,5,6). To date, c-Cbl is the only protein identified that is capable of binding to Syk at pTyr-317. Phosphorylation of Tyr-342 and 346 forms a docking site for multiple SH2 domaincontaining proteins including phospholipase C-␥, Vav, and Fgr (7-10). Mutant forms of Syk containing substitutions of Phe for Tyr-342 or both Tyr-342 and 346 exhibit a reduced ability to couple immune recognition receptors to the activation of downstream effectors such as phospholipase C-␥2 in B cells and mast cells (10, 11).Syk also is required for the activation of phosphoinositide 3-kinase (PI3K) in response to a variety of signals (12-18) including engagement of the B cell antigen receptor (BCR) (12) and macrophage or neutrophil Fc␥ receptors (13,14). Furthermore, the expression of a constitutively active ...